A1 adenosine receptor: Role in diabetes and obesity

Handbook of Experimental Pharmacology

Volumn 193, Issue , 2009, Pages 271-295

  Dhalla, Arvinder K ^a   Chisholm, Jeffrey W ^a   Reaven, Gerald M ^b   Belardinelli, Luiz ^a  

^a CV THERAPEUTICS INC   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A1 Adenosine Receptor; Antilipolytic; Diabetes; Insulin Resistance; Obesity

Indexed keywords

3 METHOXYMETHYL 5 [6 (1 [5 TRIFLUOROMETHYLPYRIDIN 2 YL]PYRROLIDIN 3 YLAMINO)PURIN 9 YL]CYCLOPENTANE 1,2 DIOL; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; 6 N CYCLOPENTYLADENOSINE; [[[[5 (6 OXOLAN 3 YL)AMINO]PURIN 9 YL] 3,4 DIHYDROXYOXOLAN 2 YL]METHOXY] N METHYLCARBOXAMIDE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; ADENYLATE CYCLASE; BW A1433U; CVT 2759; CVT 3619; CYCLIC AMP; FATTY ACID; G PROTEIN COUPLED RECEPTOR; INSULIN; N CYCLOHEXYL 2' O METHYLADENOSINE; PARTIAL AGONIST; PHENYLISOPROPYLADENOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; RECEPTOR RESERVE; RPR 749; RPR 772; SDZWAG 994; TECADENOSON; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ARTERIAL PRESSURE; BINDING AFFINITY; CONTINUOUS INFUSION; DIABETES MELLITUS; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENZYME INHIBITION; GLUCOSE TOLERANCE; HEART RATE; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; KNOCKOUT MOUSE; LIPOLYSIS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; ANIMAL; METABOLISM; PHYSIOLOGY;

ADIPOCYTES; ANIMALS; DIABETES MELLITUS; HUMANS; INSULIN RESISTANCE; LIPOLYSIS; OBESITY; RECEPTOR, ADENOSINE A1;

EID: 70349305720     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-89615-9_9     Document Type: Review

References (156)

1. Ashton TD, Baker SP, Hutchinson SA, Scammells PJ (2008) N6-Substituted C5′-modified adenosines as A1 adenosine receptor agonists. Bioorg Med Chem 16:1861-1873
2. Baker SP, Scammells PJ, Belardinelli L (2000) Differential A(1)-adenosine receptor reserve for inhibition of cyclic AMP accumulation and G-protein activation in DDT(1) MF-2 cells. Br J Pharmacol 130:1156-1164
3. Barakat H, Davis J, Lang D, Mustafa SJ, McConnaughey MM (2006) Differences in the Expression of the adenosine A1 receptor in adipose tissue of obese black and white women. J Clin Endocrinol Met 91:1882-1886
4. Bays H, Mandarino L, DeFronzo RA (2004) Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Met 89:463-478
5. Belardinelli L, Linden J, Berne RM (1989) The cardiac effects of adenosine. Prog Cardiovasc Dis 32:73-97
6. Berkich DA, Luthin DR, Woodard RL, Vannucci SJ, Linden J, LaNoue KF (1995) Evidence for regulated coupling of A1 adenosine receptors by phosphorylation in Zucker rats. Am J Physiol 268: E693-E704
7. Boden G (2001) Free fatty acids-the link between obesity and insulin resistance. Endocr Pract 7:44-51 (Pubitemid 32834246)
8. Boden G (2002) Obesity and diabetes mellitus-how are they linked?West Indian Med J 51(Suppl 1):51-54
9. Boden G, She P, Mozzoli M, Cheung P, Gumireddy K, Reddy P, Xiang X, Luo Z, Ruderman N (2005) Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-{kappa}b pathway in rat liver. Diabetes 54:3458-3465
10. Borglum JD, Vassaux G, Richelsen B, Gaillard D, Darimont C, Ailhaud G, Negrel R (1996) Changes in adenosine A1-and A2-receptor expression during adipose cell differentiation. Mol Cell Endocrinol 117:17-25
11. Brechler V, Pavoine C, Lotersztajn S, Garbarz E, Pecker F (1990) Activation of Na+ /Ca+ exchange by adenosine in ewe heart sarcolemma is mediated by a pertussis toxin-sensitive G protein. J Biol Chem 265(28):16851-16855
12. Budohoski L, Challiss RA, McManus B, Newsholme EA (1984) Effects of analogues of adenosine and methyl xanthines on insulin sensitivity in soleus muscle of the rat. FEBS Lett 167:1-4
13. Butcher RW, Ho RJ,Meng HC, Sutherland EW (1965) Adenosine 3′ ,5′-monophosphate in biological materials. II. The measurement of adenosine 3′, 5′-monophosphate in tissues and the role of the cyclic nucleotide in the lipolytic response of fat to epinephrine. J Biol Chem 240:4515-4523
14. Cappellacci L, Franchetti P, Vita P, Petrelli R, Lavecchia A, Costa B, Spinetti F, Martini C, Klotz KN, Grifantini M (2008) 5′-Carbamoyl derivatives of 2′-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 receptor from different species. Bioorg Med Chem 16:336-353
15. Carlson LA (2005) Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 258:94-114
16. Cheng JT, Chi TC, Liu IM (2000) Activation of adenosine A1 receptors by drugs to lower plasma glucose in streptozotocin-induced diabetic rats. Auton Neurosci 83:127-133
17. Ciruela F, Saura C, Canela EI, Mallol J, Lluis C, Franco R (1997) Ligand-induced phosphorylation, clustering, and desensitization of A1 adenosine receptors. Mol Pharmacol 52:788-797
18. Cox BF, Clark KL, Perrone MH, Welzel GE, Greenland BD, Colussi DJ, Merkel LA (1997) Cardiovascular and metabolic effects of adenosine A1-receptor agonists in streptozotocin-treated rats. J Cardiovasc Pharmacol 29:417-426
19. Cristalli G, Franchetti P, Grifantini M, Vittori S, Klotz KN, Lohse MJ (1988) Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives. J Med Chem 31:1179-1183
20. de Ligt RA, IJzerman AP (2002) Intrinsic activity at adenosine A1 receptors: partial and inverse agonism. Curr Pharm Des 8:2333-2344
21. Dhalla AK, Shryock JC, Shreeniwas R, Belardinelli L (2003) Pharmacology and therapeutic applications of A1 adenosine receptor ligands. Curr Top Med Chem 3:369-385
22. Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L (2006) Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. JPET 316:695-702
23. Dhalla A, Santikul M, Smith M, Wong MY, Shryock J, Belardinelli L (2007a) Anti-lipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: Comparison with nicotinic acid. JPET 321:327-333
24. Dhalla AK, Wong MY, Voshol PJ, Belardinelli L, Reaven GM (2007b) A1 adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents. Am J Physiol Endocrinol Metab 292:E1358-E1363
25. Dhalla AK, Santikul M, Chisholm JW, Belardinelli L, Reaven GM (2008) Comparison of the antilipolytic effects of an A1 adenosine receptor partial agonist in normal and diabetic rats. Diabetes Obes Metab 11:95-101
26. Dixon AK, Gubitz AK, Sirinathsinghji DJS, Richardson PJ, Freeman TC (1996) Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 118:1461-1468
27. Dobson JG Jr (1978) Reduction by adenosine of the isoproterenol-induced increase in cyclic adenosine 3′, 5′-monophosphate formation and glycogen phosphorylase activity in rat heart muscle. Circ Res 43:785-792
28. Dobson JG Jr (1983) Interaction between adenosine and inotropic interventions in guinea pig atria. Am J Physiol 245: H475-H480
29. Dobson JG Jr, Ordway RW, Fenton RA (1986) Endogenous adenosine inhibits catecholamine contractile responses in normoxic hearts. Am J Physiol 251:H455-H462
30. Dole VP (1961) Effect of nucleic acid metabolites on lipolysis in adipose tissue. J Biol Chem 236:3125-3130
31. Dong Q, Ginsberg HN, Erlanger BF (2001) Overexpression of the A1 adenosine receptor in adipose tissue protects mice from obesity-related insulin resistance. Diabetes Obes Metab 3:360-366
32. Fain JN, Malbon CC (1979) Regulation of adenylate cyclase by adenosine. Mol Cell Biochem 25:143-169
33. Fain JN, Pointer RH, Ward WF (1972) Effects of adenosine nucleosides on adenylate cyclase, phosphodiesterase, cyclic adenosine monophosphate accumulation, and lipolysis in fat cells. J Biol Chem 247:6866-6872
34. Fatholahi M, Xiang Y, Wu Y, Li Y, Wu L, Dhalla AK, Belardinelli L, Shryock JC (2006) A novel partial agonist of the A1-adenosine receptor and evidence of receptor homogeneity in adipocytes. JPET 317:676-684
35. Foley JE, Anderson RC, Bell PA, Burkey BF, Deems RO, de Souza C, Dunning BE (1997) Pharmacological strategies for reduction of lipid availability. Ann N Y Acad Sci 827:231-245
36. Fraser H, Gao Z, Ozeck MJ, Belardinelli L (2003) N-[3-(R)- Tetrahydrofuranyl]-6-aminopurine riboside, an A1 adenosine receptor agonist, antagonizes catecholamine-induced lipolysis without cardiovascular effects in awake rats. J Pharmacol Exp Ther 305:225-231
37. Fredholm BB, Sollevi A (1986) Cardiovascular effects of adenosine. Clin Physiol 6:1-21
38. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552
39. Fruhbeck G, Gomez-Ambrosi J (2002) Depot-specific differences in the lipolytic effect of leptin on isolated white adipocytes. Med Sci Monit 8:BR47-BR55
40. Fruhbeck G, Gomez-Ambrosi J, Salvador J (2001) Leptin-induced lipolysis opposes the tonic inhibition of endogenous adenosine in white adipocytes. FASEB J 15:333-340
41. Funakoshi H, Zacharia LC, Tang Z, Zhang J, Lee LL, Good JC, Herrmann DE, Higuchi Y, Koch WJ, Jackson EK, Chan TO, Feldman AM (2007) A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation 115:2307-2315
42. Gao ZG, Jacobson KA (2007) Emerging adenosine receptor agonists. Expert Opin Emerg Drugs 12:479-492
43. Gao Z, Robeva AS, Linden J (1999) Purification of A1 adenosine receptor-G-protein complexes: effects of receptor down-regulation and phosphorylation on coupling. Biochem J 338 (Pt 3):729-736
44. Gardner CJ, Twissell DJ, Coates J, Strong P (1994) The effects of GR79236 on plasma fatty acid concentrations, heart rate and blood pressure in the conscious rat. Eur J Pharmacol 257:117-121
45. Garg A, Grundy SM (1990) Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 264:723-726
46. Gines S, Ciruela F, Burgueno J, Casado V, Canela EI, Mallol J, Lluis C, Franco R (2001) Involvement of caveolin in ligand-induced recruitment and internalization of A(1) adenosine receptor and adenosine deaminase in an epithelial cell line. Mol Pharmacol 59:1314-1323
47. Gould J, Morton MJ, Sivaprasadarao A, Bowmer CJ, Yates MS (1997) Renal adenosine A1 receptor binding characteristics and mRNA levels during the development of acute renal failure in the rat. Br J Pharmacol 120:947-953
48. Grden M, Podgorska M, Szutowicz A, Pawelczyk T (2007) Diabetes-induced alterations of adenosine receptors expression level in rat liver. Exp Mol Pathol 83:392-398
49. Green A (1987) Adenosine receptor down-regulation and insulin resistance following prolonged incubation of adipocytes with an A1 adenosine receptor agonist. J Biol Chem 262:15702-15707
50. Green A, Swenson S, Johnson JL, PartinM(1989) Characterization of human adipocyte adenosine receptors. Biochem Biophys Res Commun 163:137-142
51. Green A, Johnson JL,Milligan G (1990) Down-regulation of Gi sub-types by prolonged incubation of adipocytes with an A1 adenosine receptor agonist. J Biol Chem 265:5206-5210
52. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP, for the Diabetes Multicenter Research Group (2002) Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med 162:1568-1576
53. Harada K, Shen WJ, Patel S, Natu V, Wang J, Osuga J, Ishibashi S, Kraemer FB (2003) Resistance to high-fat diet-induced obesity and altered expression of adipose-specific genes in HSL-deficient mice. Am J Physiol Endocrinol Metab 285: E1182-E1195
54. Ho RJ, Sutherland EW (1971) Formation and release of a hormone antagonist by rat adipocytes. J Biol Chem. 246:6822-6827
55. Hoffman BB, Chang H, Dall'Aglio E, Reaven GM (1986a) Desensitization of adenosine receptormediated inhibition of lipolysis. The mechanism involves the development of enhanced cyclic adenosine monophosphate accumulation in tolerant adipocytes. J Clin Invest 78:185-190
56. Hoffman BB, Dall'Aglio E, Hollenbeck C, Chang H, Reaven GM (1986b) Suppression of free fatty acids and triglycerides in normal and hypertriglyceridemic rats by the adenosine receptor agonist phenylisopropyladenosine. JPET 239:715-718
57. Ishikawa J, Mitani H, Bandoh T, Kimura M, Totsuka T, Hayashi S (1998) Hypoglycemic and hypotensive effects of 6-cyclohexyl-2′-O-methyl- adenosine, an adenosine A1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia. Diabetes Res Clin Pract 39:3-9
58. Itani SI, Ruderman NB, Schmieder F, Boden G (2002) Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 51:2005-2011
59. Jacobson KA, van Galen PJ, Williams M (1992) Adenosine receptors: pharmacology, structure- activity relationships, and therapeutic potential. J Med Chem 35:407-422
60. Jacobson KA, Von Lubitz DKJE, Daly JW, Fredholm BB (1996) Adenosine receptor ligands: differences with acute versus chronic treatment. TIPS 17:108-113
61. Jajoo S, Mukherjea D, Pingle S, Sekino Y, Ramkumar V (2006) Induction of adenosine A1 receptor expression by pertussis toxin via an adenosine 5′-diphosphate ribosylation-independent pathway. JPET 317:1-10
62. Jensen MD (2006) Adipose tissue as an endocrine organ: implications of its distribution on free fatty acid metabolism. Eur Heart J 8: B13-B19
63. Johansson SM, Salehi A, Sandstrom ME, Westerblad H, Lundquist I, Carlsson PO, Fredholm BB, Katz A (2007a) A1 receptor deficiency causes increased insulin and glucagon secretion in mice. Biochem Pharmacol 74:1628-1635
64. Johansson SM, Yang JN, Lindgren E, Fredholm BB (2007b) Eliminating the antilipolytic adenosine A1 receptor does not lead to compensatory changes in the antilipolytic actions of PGE2 and nicotinic acid. Acta Physiol 190:87-96
65. Kaartinen JM, Hreniuk SP, Martin LF, Ranta S, LaNoue KF, Ohisalo JJ (1991) Attenuated adenosine-sensitivity and decreased adenosine-receptor number in adipocyte plasma membranes in human obesity. Biochem J 279 (Pt 1):17-22
66. Kaartinen JM, LaNoue KF, Ohisalo JJ (1994) Quantitation of inhibitory G-proteins in fat cells of obese and normal-weight human subjects. Biochim Biophys Acta 1201:69-75
67. Kather H (1988) Purine accumulation in human fat cell suspensions. Evidence that human adipocytes release inosine and hypoxanthine rather than adenosine. J Biol Chem. 263:8803-8809
68. Kenakin TP (1984) The classification of drugs and drug receptors in isolated tissues. Pharmacol Rev 36:165-222
69. Kenakin TP, Bond RA, Bonner TI (1992) Definition of pharmacological receptors. Pharmacol Rev 44:351-362
70. Klotz KN (2000) Adenosine receptors and their ligands. Naunyn-Schmiedeberg's Arch Pharmacol 362:382-391
71. Klotz K-N, Lohse MJ, Schwabe U, Cristalli G, Vittori S, Grifantini M (1989) 2-Chloro-N6- [3H]cyclopentyladenosine ([3H]CCPA): a high 1 affinity agonist radioligand for A1 adenosine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 340:679-683
72. Kollias-Baker C, Shryock JC, Belardinelli L (1995) Myocardial adenosine receptors. In: Belardinelli L, Pelleg A (eds) Adenosine and adenine nucleotides: from molecular biology to integrative physiology. Kluwer, Boston, pp 221-228
73. Kollias-Baker CA, Ruble J, Jacobson M, Harrison JK, Ozeck M, Shryock JC, Belardinelli L (1997) Agonist-independent effect of an allosteric enhancer of the A1 adenosine receptor in CHO cells stably expressing the recombinant human A1 receptor. JPET 281:761-768
74. Kovoor A, Celver JP, Wu A, Chavkin C (1998) Agonist induced homologous desensitization of mu-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy. Mol Pharmacol 54:704-711
75. Lai DM, Tu YK, Liu IM, Cheng JT (2005) Increase of adenosine A1 receptor gene expression in cerebral ischemia of Wistar rats. Neurosci Lett 387:59-61
76. Langin D (2006) Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. Pharmacol Res 53:482-491
77. LaNoue KF, Martin LF (1994) Abnormal A1 adenosine receptor function in genetic obesity. FASEB J 8:72-80
78. Large V, Arner P (1998) Regulation of lipolysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidaemia. Diabet Metab 24:409-418
79. Larrouy D, Galitzky J, Lafontan M (1991) A1 adenosine receptors in the human fat cell: tissue distribution and regulation of radioligand binding. Eur J Pharmacol 206:139-147
80. Lasley RD, Narayan P, Uittenbogaard A, Smart EJ (2000) Activated cardiac adenosine A1 receptors translocate out of caveolae. J Biol Chem 275:4417-4421
81. Leblanc J, Soucy J (1994) Hormonal dose-response to an adenosine receptor agonist. Can J Physiol Pharmacol 72:113-116
82. Leung E, Jacobson KA, Green RD (1990) Analysis of agonist-antagonist interactions at A1 adenosine receptors. Mol Parmacol 38:72-83
83. Liang HX, Belardinelli L, Ozeck MJ, Shryock JC (2002) Tonic activity of the rat adipocyte A1- adenosine receptor. Br J Pharmacol 135:1457-1466
84. Linden J (1991) Structure and function of A1 adenosine receptors. FASEB J 5:2668-2676
85. Liu IM, Tzeng TF, Tsai CC, Lai TY, Chang CT, Cheng JT (2003) Increase in adenosine A1 receptor gene expression in the liver of streptozotocin-induced diabetic rats. Diabet Metab Res Rev 19:209-215
86. Lohse MJ, Ukena D, Schwabe U (1984) Adenosine receptors on heart muscle. Lancet 2:355
87. Londos C, Wolff J (1977) Two distinct adenosine-sensitive sites on adenylate cyclase. Proc Natl Acad Sci USA 74:5482-5486
88. Longabaugh JP, Didsbury J, Spiegel A, Stiles GL (1989) Modification of the rat adipocyte A1 adenosine receptor-adenylate cyclase system during chronic exposure to an A1 adenosine receptor agonist: alterations in the quantity of Gs alpha and Gi alpha are not associated with changes in their mRNAs. Mol Pharmacol 36:681-688
89. Lorenzen A, Sebastiao AM, Sellink A, Vogt H, Schwabe U, Ribeiro JA, IJzerman AP (1997) Biological activities of N6, C8-disubstituted adenosine derivatives as partial agonists at rat brain adenosine A1 receptors. Eur J Pharmacol 334:299-307
90. Mathot RAA, van der Wenden EM, Soudijn W, IJzerman AP, Danhof M (1995) Deoxyribose analogues of N6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo. Br J Pharmacol 116:1957-1964
91. McKenny JM, Proctor JD, Harris S, Chinchili VM (1994) A comparison of the efficacy and toxic effects of sustained vs immediate-release niacin in hypercholesterolemic patients. JAMA 271:672-710
92. Merkel LA, Hawkins ED, Colussi DJ, Greenland BD, Smits GJ, Perrone MH, Cox BF (1995) Cardiovascular and antilipolytic effects of the adenosine agonist GR79236. Pharmacology 51:224-236
93. Meyer P, Bier D, Holschbach M, Cremer M, Tellmann L, Bauer A (2003) In vivo imaging of rat brain A1 adenosine receptor occupancy by caffeine. Eur J Nucl Med Mol Imag 30:1440
94. Moreno FJ, Mills I, Garcia-Sainz JA, Fain JN (1983) Effects of pertussis toxin treatment on the metabolism of rat adipocytes. J Biol Chem 258(18):10938-10943
95. Morey TE, Belardinelli L, Dennis DM (1998) Validation of Furchgott's method to determine agonist-dependent A1-adenosine receptor reserve in guinea-pig atrium. Br J Pharmacol 123:1425-1433
96. Morrison CF, Elzein E, Jiang B, Ibrahim PN, Marquart T, Palle V, Shenk KD, Varkhedkar V, Maa T,Wu L,Wu Y, Zeng D, Fong I, Lustig D, Leung K, Zablocki JA (2004) Structure-affinity relationships of 5′-aromatic ethers and 5′-aromatic sulfides as partial A1 adenosine agonists, potential supraventricular anti-arrhythmic agents. Bioorg Med Chem Lett 14:3793-3797
97. Muller CE (2001) A1 adenosine receptors and their ligands: overview and recent developments. Il Farmaco 56:77-80
98. Munshi R, Pang IH, Sternweis PC, Linden J (1991) A1 adenosine receptors of bovine brain couple to guanine nucleotide-binding proteins Gi1, Gi2, and Go. J Biol Chem 266:22285-22289
99. Murray TF (1982) Up-regulation of rat cortical adenosine receptors following chronic administration of theophylline. Eur J Pharmacol 82:113-114
100. Nemeth ZH, Bleich D, Csoka B, Pacher P, Mabley JG, Himer L, Vizi ES, Deitch EA, Szabo C, Cronstein BN, Hasko G (2007) Adenosine receptor activation ameliorates type 1 diabetes. FASEB J 21:2379-2388
101. Nie Z, Mei Y, Ford M, Rybak L, Marcuzzi A, Ren H, Stiles GL, Ramkumar V (1998) Oxidative stress increases A1 adenosine receptor expression by activating nuclear factor kappa B. Mol Pharmacol 53:663-669
102. Okajima F, Sato K, Sho K, Kondo Y (1989) Stimulation of adenosine receptor enhances A1-adrenergic receptor-mediated activation of phospholipase C and Ca2+ mobilization in a pertussis toxin-sensitive manner in FRTL-5 thyroid cells. FEBS Lett 248:145-149
103. Osuga J, Ishibashi S, Oka T, Yagyu H, Tozawa R, Fujimoto A, Shionoiri F, Yahagi N, Kraemer FB, Tsutsumi O, Yamada N (2000) Targeted disruption of hormone-sensitive lipase results in male sterility and adipocyte hypertrophy, but not in obesity. Proc Natl Acad Sci USA 97:787-792
104. Palle VP, Varkhedkar V, Ibrahim P, Ahmed H, Li Z, Gao Z, Ozeck M,Wu Y, Zeng D,Wu L, Leung K, Chu N, Zablocki JA (2004) Affinity and intrinsic efficacy (IE) of 5′-carbamoyl adenosine analogues for the A1 adenosine receptor-efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF). Bioorg Med Chem Lett 14:535-539
105. Palmer TM, Benovic JL, Stiles GL (1996) Molecular basis for subtype-specific desensitization of inhibitory adenosine receptors. Analysis of a chimeric A1-A3 adenosine receptor. J Biol Chem 271:15272-15278
106. Parsons WJ, Stiles GL (1987) Heterologous desensitization of the inhibitory A1 adenosine receptor-adenylate cyclase system in rat adipocytes. Regulation of both Ns and Ni. J Biol Chem 262:841-847
107. Pawelczyk T, Grden M, Rzepko R, Sakowicz M, Szutowicz A (2005) Region-specific alterations of adenosine receptors expression level in kidney of diabetic rat. Am J Pathol 167:315-325
108. Poulsen S, Quinn RJ (1998) Adenosine receptors: new opportunities for future drugs. Bioorg Med Chem 6:619-641
109. Poynten AM, Gan SK, Kriketos AD, O'Sullivan A, Kelly JJ, Ellis BA, Chisholm DJ, Campbell LV (2003) Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism 52:699-704
110. Press NJ, Gessi S, Borea PA, Polosa R (2007) Therapeutic potential of adenosine receptor antagonists and agonists. Expert Opin Ther Patents 17:979-991
111. Qu X, Cooney G, Donnelly R (1997) Short-term metabolic and haemodynamic effects of GR79236 in normal and fructose-fed rats. Eur J Pharmacol 338:269-276
112. Ramkumar V, Bumgarner JR, Jacobson KA, Stiles GL (1988) Multiple components of the A1 adenosine receptor-adenylate cyclase system are regulated in rat cerebral cortex by chronic caffeine ingestion. J Clin Invest 82:242-247
113. Reaven GM (1995) The fourth musketeer: from Alexandre Dumas to Claude Bernard. Diabetologia 38:3-13
114. Reaven GM, Chang H, Ho H, Jeng CY, Hoffman BB (1988) Lowering of plasma glucose in diabetic rats by antilipolytic agents. Am J Physiol 254:E23-E30
115. Reppert SM, Weaver DR, Stehle JH, Rivkees SA (1991) Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord. Mol Endocrin 5:1037-1048
116. Rivkees SA (1995) The ontogeny of cardiac and neural A1 adenosine receptor expression in rats. Dev Brain Res 89:202-213
117. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI (1996) Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97:2859-2865
118. Rogachev B, Ziv NY, Mazar J, Nakav S, Chaimovitz C, Zlotnik M, Douvdevani A (2006) Adenosine is upregulated during peritonitis and is involved in downregulation of inflammation. Kidney Int 70:675-681
119. Rolband GC, Furth ED, Staddon JM, Rogus EM, Goldberg AP (1990) Effects of age and adenosine in the modulation of insulin action on rat adipocyte metabolism. J Gerontol 45:B174-B178
120. Ruffolo RR (1982) Important concepts of receptor theory. J Auton Pharmacol 2:277-295
121. Saggerson ED, Jamal Z (1990) Differences in the properties of A1-type adenosine receptors in rat white and brown adipocytes. Biochem J 269:157-161
122. Sako Y, Grill VE (1990) A 48-h lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 127:1580-1589
123. Schiffmann SN, Libert F, Vassart G, Dumont JE, Vanderhaeghen JJ (1990) A cloned G proteincoupled protein with a distribution restricted to striatal medium-sized neurons. Possible relationship with D1 dopamine receptor. Brain Res 519:333-337
124. Schoelch C, Kuhlmann J, Gossel M, Mueller G, Neumann-Haefelin C, Belz U, Kalisch J, Biemer-Daub G, KramerW, Juretschke HP, Herling AW(2004) Characterization of adenosine- A1 receptor-mediated antilipolysis in rats by tissue microdialysis, 1H-spectroscopy, and glucose clamp studies. Diabetes 53:1920-1926
125. Schrader J, Baumann G, Gerlach E (1977) Adenosine as inhibitor of myocardial effects of catecholamines. Pflugers Arch 372:29-35
126. Schwabe U, Ebert R (1974) Stimulation of cyclic adenosine 3′ , 5′-monophosphate accumulation and lipolysis in fat cells by adenosine deaminase. Naunyn-Schmiedeberg's Arch Pharmacol 282:33-44
127. Schwabe U, Ebert R, Erbler C (1973) Adenosine release from isolated fat cells and its significance for the effects of hormones on cyclic 3′, 5′-AMP levels and lipolysis. Naunyn-Schmiedeberg's Arch Pharmacol 276:133-148
128. Schwabe U, Schonhofer PS, Ebert R (1974) Facilitation by adenosine of the action of insulin on the accumulation of adenosine 3′, 5′-monophosphate, lipolysis, and glucose oxidation in isolated fat cells. Eur J Biochem 46:537-545
129. Shah B, Rohatagi S, Natarajan C, Kirkesseli S, Baybutt R, Jensen BK (2004) Pharmacokinetics, pharmacodynamics, and safety of a lipid-lowering adenosine A1 agonist, RPR749, in healthy subjects. Am J Ther 11:175-189
130. Shen J, Halenda SP, Sturek M, Wilden P (2005) Novel mitogenic effect of adenosine on coronary artery smooth muscle cells. Circ Res 96:982-990
131. Srinivas M, Shryock JC, Dennis DM, Baker SP, Belardinelli L (1997) Differential A1 adenosine receptor reserve for two actions of adenosine on guinea pig atrial myocytes. Mol Pharmacol 52:683-691
132. Stephenson RP (1997) A modification of receptor theory. 1956. Br J Pharmacol 120:106-120
133. Strange PG (2008) Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. Br J Pharmacol 153:1353-1363
134. Strong P, Anderson R, Coates J, Ellis F, Evans B, Gurden MF, Johnstone J, Kennedy I, Martin DP (1993) Suppression of non-esterified fatty acids and triacylglycerol in experimental animals by the adenosine analogue GR79236. Clin Sci 84:663-669
135. Szot P, Sanders RC, Murray TF (1987) Theophylline-induced upregulation of A1-adenosine receptors associated with reduced sensitivity to convulsants. Neuropharmacology 26:1173-1180
136. Takasuga S, Katada T, Ui M, Hazeki O (1999) Enhancement by adenosine of insulin-induced activation of phosphoinositide 3-kinase and protein kinase B in rat adipocytes. J Biol Chem 274:19545-19550
137. Tatsis-Kotsidis I, Erlanger BF (1999) Initiation of a process of differentiation by stable transfection of ob17 preadipocytes with the cDNA of human A1 adenosine receptor. Biochem Pharmacol 58:167-170
138. Thompson CS, Strong P, Mikhailidis DP (1994) Interactions between insulin and the antilipolytic agent GR79236 in ketoacidotic diabetic rats. J Drug Dev 6:183-186
139. Trost T, Schwabe U (1981) Adenosine receptors in fat cells. Identification by (-)-N6- [3H]phenylisopropyladenosine binding. Mol Pharmacol 19:228-235
140. Ukena D, Furler R, Lohse MJ, Engel G, Schwabe U (1984a) Labelling of Ri adenosine receptors in rat fat cell membranes with (-)-[125iodo]N6- hydroxyphenylisopropyladenosine. Naunyn-Schmiedeberg's Arch Pharmacol 326:233-240
141. Ukena D, Poeschla E, Schwabe U (1984b) Guanine nucleotide and cation regulation of radioligand binding to Ri adenosine receptors of rat fat cells. Naunyn-Schmiedeberg's Arch Pharmacol 326:241-247
142. Vachon L, Costa T, Herz A (1987) Opioid receptor desensitization in NG 108-115cells. Differential effects of a full and a partial agonist on the opioid-dependent GTPase. Biochem Pharmacol 36:2889-2897
143. Van der Graaf PH, van Schaick EA, Visser SAG, De Greef HJMM, IJzerman AP, Danhof M (1999) Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A1 receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. J Pharmacol Exp Ther 290:702-709
144. van der Wenden EM, von Frijtag Drabbe Kunzel JK,Mathot RA, Danhof M, IJzerman AP, Soudijn W (1995) Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor. J Med Chem 38:4000-4006
145. van Schaick EA, Tukker HE, Roelen HCPF, IJzerman AP, Danhof M (1998a) Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: haemodynamic versus antilipolytic responses in rats. Br J Pharmacol 124:607-618
146. van Schaick EA, Zuideveld KP, Tukker HE, Langemeijer MW, IJzerman AP, Danhof M (1998b) Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(psulfophenyl) adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. JPET 287:21-30
147. van Tilburg EW, van der Klein PA, Frijtag Drabbe KJ, de Groote M, Stannek C, Lorenzen A, IJzerman AP (2001) 5′-O-Alkyl ethers of N,2-substituted adenosine derivatives: partial agonists for the adenosine A1 and A3 receptors. J Med Chem 44:2966-2975
148. Vannucci SJ, Klim CM, Martin LF, LaNoue KF (1989) A1-adenosine receptor-mediated inhibition of adipocyte adenylate cyclase and lipolysis in Zucker rats. Am J Physiol 257: E871-E878
149. Vassaux G, Gaillard D, Mari B, Ailhaud G, Negrel R (1993) Differential expression of adenosine A1 and A2 receptors in preadipocytes and adipocytes. Biochem Biophys Res Commun 193:1123-1130
150. Vega GL, Cater NB, Meguro S, Grundy SM (2005) Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol 95:1309-1313
151. Wagner H, Milavec-Krizman M, Gadient F, Menninger K, Schoeffter P, Tapparelli C, Pfannkuche H-J, Fozard JR (1995) General pharmacology of SDZ WAG 994, a potent selective and orally active adenosine A1 receptor agonist. Drug Dev Res 34:276-288
152. Wu SN, Linden J, Visentin S, Boykin M, Belardinelli L (1989) Enhanced sensitivity of heart cells to adenosine and up-regulation of receptor number after treatment of guinea pigs with theophylline. Circ Res 65:1066-1077
153. Wu L, Belardinelli L, Zablocki JA, Palle V, Shryock JC (2001) A partial agonist of the A(1)- adenosine receptor selectively slows AV conduction in guinea pig hearts. Am J Physiol Heart Circ Physiol 280:H334-H343
154. Wyne KL (2003) Free fatty acids and type 2 diabetes mellitus. Am J Med 115(Suppl 8A):29S-36S
155. Xu B, Berkich DA, Crist GH, LaNoue KF (1998) A1 adenosine receptor antagonism improves glucose tolerance in Zucker rats. Am J Physiol 274:E271-E279
156. Zannikos PN, Rohatagi S, Jensen BK (2001) Pharmacokinetic-pharmacodynamic modeling of the antilipolytic effects of an adenosine receptor agonist in healthy volunteers. J Clin Pharmacol 41:61-69